173 related articles for article (PubMed ID: 31786838)
1. Current and future targets and therapies in metastatic colorectal cancer.
Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
[TBL] [Abstract][Full Text] [Related]
2. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
Spiliopoulou P; Arkenau HT
World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL; Lenz HJ
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
[TBL] [Abstract][Full Text] [Related]
4. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
Djanani A; Eller S; Öfner D; Troppmair J; Maglione M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256240
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
Coppedè F; Lopomo A; Spisni R; Migliore L
World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EGFR signalling pathway in metastatic colorectal cancer.
Napolitano S; Martini G; Ciardiello D; Del Tufo S; Martinelli E; Troiani T; Ciardiello F
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):664-676. PubMed ID: 38697174
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Taieb J; Jung A; Sartore-Bianchi A; Peeters M; Seligmann J; Zaanan A; Burdon P; Montagut C; Laurent-Puig P
Drugs; 2019 Sep; 79(13):1375-1394. PubMed ID: 31347092
[TBL] [Abstract][Full Text] [Related]
8. Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.
Filip S; Vymetalkova V; Petera J; Vodickova L; Kubecek O; John S; Cecka F; Krupova M; Manethova M; Cervena K; Vodicka P
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722130
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer.
Patelli G; Mauri G; Tosi F; Amatu A; Bencardino K; Bonazzina E; Pizzutilo EG; Villa F; Calvanese G; Agostara AG; Stabile S; Ghezzi S; Crisafulli G; Di Nicolantonio F; Marsoni S; Bardelli A; Siena S; Sartore-Bianchi A
Clin Cancer Res; 2023 Nov; 29(22):4530-4539. PubMed ID: 37436743
[TBL] [Abstract][Full Text] [Related]
10. Metastatic colorectal cancer- third line therapy and beyond.
Foo T; Roy A; Karapetis C; Townsend A; Price T
Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
[TBL] [Abstract][Full Text] [Related]
11. Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.
Crutcher MM; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1317-1326. PubMed ID: 36259230
[TBL] [Abstract][Full Text] [Related]
12. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer.
Martínez-Pérez J; Torrado C; Domínguez-Cejudo MA; Valladares-Ayerbes M
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892410
[TBL] [Abstract][Full Text] [Related]
13. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance.
Kusumaningrum AE; Makaba S; Ali E; Singh M; Fenjan MN; Rasulova I; Misra N; Al-Musawi SG; Alsalamy A
Cell Biochem Funct; 2024 Jan; 42(1):e3906. PubMed ID: 38269502
[TBL] [Abstract][Full Text] [Related]
14. Translational research of new developments in targeted therapy of colorectal cancer.
Yang L; Atakhanova N; Arellano MTC; Mohamed MY; Hani T; Fahdil AA; Castillo-Acobo RY; Juyal A; Hussein AK; Amin AH; Pecho RDC; Akhavan-Sigari R
Pathol Res Pract; 2023 Dec; 252():154888. PubMed ID: 37948996
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.
Li F; Lin Y; Li R; Shen X; Xiang M; Xiong G; Zhang K; Xia T; Guo J; Miao Z; Liao Y; Zhang X; Xie L
Front Pharmacol; 2023; 14():1165666. PubMed ID: 37927605
[TBL] [Abstract][Full Text] [Related]
16. New developments in targeted therapy for metastatic colorectal cancer.
Wong AHN; Ma B; Lui RN
Ther Adv Med Oncol; 2023; 15():17588359221148540. PubMed ID: 36687386
[TBL] [Abstract][Full Text] [Related]
17. A decade of progress: advances in the third-line treatment of patients with metastatic colorectal cancer.
Bekaii-Saab T
Am J Manag Care; 2024 May; 30(2 Suppl):S23-S30. PubMed ID: 38701363
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.
Riechelmann R; Grothey A
Ther Adv Med Oncol; 2017 Feb; 9(2):106-126. PubMed ID: 28203302
[TBL] [Abstract][Full Text] [Related]
19. Signaling pathways in colorectal cancer implications for the target therapies.
Song Y; Chen M; Wei Y; Ma X; Shi H
Mol Biomed; 2024 Jun; 5(1):21. PubMed ID: 38844562
[TBL] [Abstract][Full Text] [Related]
20. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature.
Guerrero P; Albarrán V; San Román M; González-Merino C; García de Quevedo C; Moreno J; Calvo JC; González G; Orejana I; Chamorro J; Martínez-Delfrade Í; Morón B; de Frutos B; Ferreiro MR
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
